MitoSciences Inc and the University of Oregon (UO) today announced the completion of an exclusive commercial license for a suite of biotechnology innovations. The agreement is associated with a portfolio of monoclonal antibodies that are being used by MitoSciences to develop tests for cell-based drug toxicity screening and for multiplexing assays used to generate mitochondrial protein biomarkers for diagnostics and personalized medicine. The antibodies are sold individually and in kits to the life science research market.